New research from Queen Mary University of London (QMUL) reveals taking aspirin can significantly reduce the risk of developing – and dying from – the major cancers of the digestive tract, i.e. bowel, stomach and oesophageal cancer.
For the first time, scientists have reviewed all the available evidence from many studies and clinical trials assessing both the benefits and harms of preventive use of aspirin. Conclusions of the study, funded by Cancer Research UK among others, are published today in the leading cancer journal Annals of Oncology*.
The researchers, led by Professor Jack Cuzick, Head of QMUL's Centre for Cancer Prevention (London, UK), found taking aspirin for 10 years could cut bowel cancer cases by around 35% and deaths by 40%. Rates of oesophageal and stomach cancers were cut by 30% and deaths from these cancers by 35-50%.
To reap the benefits of aspirin, the evidence shows people need to start taking a daily dose of 75-100 mg for at least five years and probably 10 years between the ages of 50 and 65. No benefit was seen whilst taking aspirin for the first three years, and death rates were only reduced after five years.
However, the research also warns taking aspirin long-term increases the risk of bleeding from the digestive tract, e.g. stomach bleeding. Amongst 60-year-old individuals who take daily aspirin for 10 years, the risk of digestive tract bleeds increases from 2.2% to 3.6%, and this could be life-threatening in a very small proportion (less than 5%) of people.
Overall, rates of serious or fatal gastrointestinal bleeding are very low under the age of 70, but increased sharply after that age. Another side effect of aspirin use is peptic ulcer, the risk of which is increased by 30-60%.
The study also uncovers uncertainty over the most appropriate dose of aspirin required to maximize the benefit / harm ratio, with doses varying between 75 mg to 325mg a day in different clinical trials and studies. It is also not clear whether taking aspirin for longer than 10 years will result in greater benefits.
Professor Jack Cuzick, Queen Mary University of London, comments: "It has long been known that aspirin – one of the cheapest and most common drugs on the market – can protect against certain types of cancer. But until our study, where we analysed all the available evidence, it was unclear whether the pros of taking aspirin outweighed the cons.
"Whilst there are some serious side effects that can't be ignored, taking aspirin daily looks to be the most important thing we can do to reduce cancer after stopping smoking and reducing obesity, and will probably be much easier to implement."
"Our study shows that if everyone aged between 50-65 started taking aspirin daily for at least 10 years, there would be a 9% reduction in the number of cancers, strokes and heart attacks overall in men and around 7% in women. The total number of deaths from any cause would also be lower, by about 4% over a 20-year period. The benefits of aspirin use would be most visible in the reduction in deaths due to cancer.
"The risk of bleeding depends on a number of known factors which people need to be aware of before starting regular aspirin and it would be advisable to consult with a doctor before embarking on daily medication."
Further research is now needed to define more clearly who will benefit most greatly from taking aspirin and who is most at risk of the bleeding side effects.
For more information contact:
PR Manager (School of Medicine and Dentistry)
Queen Mary University of London
Tel: 44 (0)20 7882 7943 / 44 (0)7709 825 741
Notes to the editor
Annals of Oncology
Mobile: +44 (0)7711 296 986
Notes to the editor
* "Estimates of benefits and harms of prophylactic use of aspirin in the general population", by J. Cuzick et al. Annals of Oncology. doi:10.1093/annonc/mdu225
An embargoed pdf of the full paper can be downloaded before publication by journalists at: http://www.oxfordjournals.org/our_journals/annonc/prpaper.pdf
N.B. Journalists: please don't use this link in any stories that you publish. It is for the exclusive use of the media BEFORE publication. After publication the paper will be replaced, so please link to the published paper on the Annals of Oncology website: http://annonc.oxfordjournals.org/content/early/recent.
About Queen Mary University of London
Queen Mary University of London is among the UK's leading research-intensive higher education institutions, with five campuses in the capital: Mile End, Whitechapel, Charterhouse Square, West Smithfield and Lincoln's Inn Fields.
A member of the Russell Group, Queen Mary is also one of the largest of the colleges of the University of London, with 17,800 students - 20 per cent of whom are from more than 150 countries. Some 4,000 staff deliver world-class degrees and research across 21 departments, within three Faculties: Science and Engineering; Humanities and Social Sciences; and the School of Medicine and Dentistry.
Queen Mary has an annual turnover of £350m, research income worth £100m, and generates employment and output worth £700m to the UK economy each year. Unique for London universities, Queen Mary has an integrated residential campus in Mile End - a 2,000-bed award-winning Student Village overlooking the scenic Regents Canal.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.